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Reaction of 4-(N-2-chlorocthyl-~-methylamino)benzylphosphamidcs of oligonucleotides (RCI-(pT),, and RCl-(pApC),) with human chromatin in 
intact nuclei and with metaphase chromosomes has been investigated. The oligonuclcotides were targeted to poiy(A) and poly(TG)-repeating DNA 
sequences, It was found that the reagents alkylate DNA and some proteins due to specificcomplex formation. The affinity character of the reaction 
was proved by the fact that free corresponding oligonucleotides taken in excess or preliminary treatment ofchromatin with S,-nucleas both prevent 
the biopolymers from modification. The results obtained evidence that in human chromatin there are open DNA sequences available for affinity 
modification with oligonucleotide derivatives. Analysis of patterns of modified proteins within these chromatin areas may give a key to the structure 
of these chromatin sites. 
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I, INTRODUCTION 
Oligonucleotide derivatives capable of binding to spe 
cific target nucleic acids and affect their functions are 
becoming an efficient ool of nuclear biologists and they 
are considered as potential therapeutics exerting their 
action at the level of genome functioning (for reviews 
see [1,2]). Recent progress in development of oligonucle- 
otide derivatives targeted to single-stranded nucleic 
acids has stimulated esign of the derivatives for target- 
ing double-stranded DNA [3-61, It was found that de- 
rivatives of pyrimidine and purine oligonucleotides can 
form specific triple-stranded complexes with corre- 
sponding oligopurine-oligopyrimidine stretches in 
dsDNA. Although such sequences are often found in 
viral and mammalian DNA, approaches for targeting 
arbitrary nucleotide sequences in dsDNA remain to be 
developed. The problem of targeting DNA at any site 
may be solved if the molecule is locally unwound, ex- 
posing single-stranded sequence which can form com- 
plementary complexes with oligonucleotides. One could 
expect that local unwinding of DNA occurs naturally 
in the course of transcription and replication. In our 
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experiments on affinity modification of DNA in murine 
chromatin with alkylating derivatives of oligonucleo- 
tides we have found that the derivatives indeed can form 
complementary complexes with some single-stranded 
regions of the chromatin DNA, although the nature of 
these regions is perhaps different from those appearing 
due to replication and transcription [7-l 11. 
In the present paper, we report the results of se- 
quence-specific chemical modification of human chro- 
matin with 4-(N-2-chloro-ethyl-ll’-methylamino)benzyl- 
phosphamides of oligonucleotides which are targeted to 
oligo(A) and oligo(TG)-sequences. 
2. MATERIALS AND METHODS 
Chemicals and enzymes were from Sigma and Merck. [y-‘?P]ATP 
of high specific activity (%tOO Ci/mmol) was obtained from the InsIi- 
tate of Nuclear Physics, Uzbek Academy of Sciences, Oligonucleo- 
tides and the alkylating derivatives were synthesized according to the 
described methods [12,13]. Lsbeling ofoligonucleotides at the Y-end 
was done with polynucleotide kinase and [y-“PJATP [14]. The nuclei 
from Hcla cells and metaphase clrromosomes were isolated by the 
procedure described in [9.15]. Chromatin was incubated with 1 x W 
M oligonucleotide derivatives iu buffer I (buffer I: 0.34 M sucrose. 
4 mM EDTA, 60 mM KCI. I5 mM NaCI, 4 mM CaQ, 0.15 mM 
Tris-HCI, pH 7.6) for 20 hat 25°C. DNA was isolated fromchromatin 
by phenol extraction at pH 8 in the presence of 0.5% SDS aficr 
treatment of chromatin with ribonuclease A and proteinase K or DNA 
was separated from proteins by ultracentrifugation according to [IO]. 
Protein’s upematant was dialyzed against 0.01 M Tris-HCI, pH 7.3. 
0. I mM PMSF and incubated with a micrococca I nuclcasc to rcniouc 
the oiigonuclcotidc moiety crosslinked to the proteins [IO] and was 
analyscd by electrophorcsis accordins to [t6]. The extent of DNA 
modification was c&u&d nficr the co~~pkt: rcmo~d of thr: COXOU- 
pled oligonuclcotide derlxtives from the DNA by gelchromatogra- 
phy on Scphadex G-100 under dissociating conditions (7 M urea). 
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Fig. I. Relative extent of DNA modification in Hela nuclei with 
RCI-[“PI-(pT),(, (I) and RCI-[‘?P]-(pApC), (2). M = modification ex- 
tent, moles of reagent per lo6 moles of DNA nucleotides. (m) Moditi- 
cation without addition of free oligonucleotides; (@) modification in 
the presence of IO-fold excess of free oligonucleotide; (0) modification 
after preliminary treatment of nuclei by S,-nuclease. 
3. RESULTS AND DISCUSSION 
Since the nuclear membrane is permeable for al- 
kylating derivatives of oligonucleotides [lo], in this 
study intact Hela nuclei were treated with the reagents 
RCl-[3zP]-(pdT),, and RCl-[32P]-(pdApdC),. These ol- 
igonucleotides are targeted to the oligo(A)- and 
oligo(TG)-repeats of DNA which are widely distributed 
in eukaryotic DNA. 
Fig. 1 shows the results of the experiment. DNA of 
the Hela interphase nuclei is substantially more availa- 
ble for modification with the RC1-[3’P]-(pdApdC), than 
with the RCI-[3’P]-(pd’I)I,. The excess of the cold ol- 
igonucleotide of a same sequence, as the reagent, con- 
siderably decreases the extent of modification, thus sug 
gesting sequence-specific processes in both cases. It 
should be emphasized that deproteinated DNA from 
the same cells does not react with the oligonucleotide 
derivatives, which means that the chromatin DNA 
should have some structural features allowing oligonu- 
cleotide binding; it can rather be attributed probably to 
the existence of the strongly negatively supercoiled 
DNA regions (open single-stranded sequences or re- 
gions where DNA can unwind in the presence of ol- 
igonucleotides). 
It was shown that the extent of DNA modification 
was not influenced by the additional treatment with 
ribonuclease under dissociating conditions (7 ?$I urea). 
Therefore the oligonucleotide binding cannot be attri- 




Fig, 2, Relative extent of DNA modification in mctaphase chromo- 
some with RCI-[“P]-(pT),6 (I) and RCI-f’?P]-(pApC), (2). M = modi- 
tication extent, moles of reagent per IO6 moles of DNA nucleotidcs. 
(a) Modification without addition of free oligonucleotidcs: (a) modifi- 
cation in the presence of IO-fold excess of free oligonucleotide: (0) 
modification after preliminary treatment of chromosome by 
S,-nuclease. 
Mild preliminary treatment of the nuclei with S,-nu- 
clease, which digests ingle-stranded parts of chromatin 
DNA, prevents the DNA from modification with ol- 
igonucleotidc derivatives. This suggests that in both 
cases the reaction proceeds with single-stranded DNA 
sequences via formation of the double-stranded com- 
plexes. Fig. 2 demonstrates that specific chemical mod- 
ification of DNA in metaphase chromosome can also 
occur although less efficiently as compared to the inter- 
phase nuclei, particularly for the (pApC),-derivative. 
It was found that CIR-PT),~ and CIl<-(pApC)6 react 
also with chromatin proteins (Fig. 3). From the data 
shown in Fig. 3 it is seen that the two reagents label 
different sets of proteins. Nine proteins are labeled with 
ClR-(pT),, and 14 with clR-(pA~c)~ I3 intact inter- 
phase Hela nuclei. Four proteins from Hela nuclei 
treated with RCl-(pT),, are alkylated specifically (mo- 
lecular masses about 19, 47, 61, >66 kDa), since their 
modification was inhibited both by excess of the cold 
(PT),~ and by preliminary S,-nuclease treatment of nu- 
clei (Fig. 3). A more complex set of modified proteins 
was obtained by treatment of Hela nuclei with RCI- 
(pApC& among the 14 modified proteins at least 7 (with 
molecular masses near 19.5,21,25.5,31,33,43 and >66 
kDa) were alkylated specifically. These proteins were 
protected from the reagent by the excess of free (PApQ 
and the reaction required the presence of single- 
stranded DNA parts. These results suggest hat these 
specifically modified proteins :re located near the corre- 
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Fig. 3. Analysis of modified chromatin proteins by SDStlectrophore. 
sis. (Lane 1) Modification with RCl-[‘zP]-(pT),a; (lane 2) modification 
with RCI-[‘*P].(pT),, in the presence of lo-fold excess of free (pdT),,; 
(lane 3) modification with RCI-[‘lP]-(pT),, after preliminary treatment 
by S,-nuclease; (lane 4) modification with RCI.[3zP]+ApC)s; (lane 5) 
modilication with RCI-[‘2P]-(pApC), in the presence of excess of free 
(pApC&; (lane 6) modification with RCI-[3zP]-(pApC), after prelimi- 
nary treatment by S,-nuclease. 
sponding target nucleotide sequences which are availa- 
ble for the complex formation. 
The results obtained provide evidence that there are 
open DNA sequences in human chromatin which can 
be affinity-modified by oligonucleotide derivatives. 
Analysis of modified proteins within these chromatin 
areas may give a key to the structure of these chromatin 
sites. 
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